Medulloblastoma: Molecular understanding, treatment evolution, and new developments
Introduction
Medulloblastoma (MB) is a high-grade malignancy that was initially described in 1925 as a distinct series of childhood cerebellum tumors. MB dominantly occurs in infancy (ages less than 3 years) and childhood (ages younger than 16 years) and now represents the most common childhood malignant brain tumor accounting for nearly 20–30% of all pediatric central nervous tumors in children (Ostrom et al., 2015; Pui, Gajjar, Kane, Qaddoumi, & Pappo, 2011).
MB generally occurs in the posterior fossa, making its diagnosis and treatment much challenging and often delayed. In the 1930s, surgical intervention was the only treatment option for MB; however, the immediate post-operative mortality rate was found higher than 30% (Millard & De Braganca, 2016). Until the 1950s, craniospinal irradiation was introduced as an adjuvant treatment following surgical resection and showed improved survival rates. Unfortunately, serious motor and cognitive adverse effects, including neurocognitive impairment, secondary malignancies, and endocrine dysfunction were observed in younger patients (Millard & De Braganca, 2016; Paterson & Farr, 1953). Since the 1970s, non-specific cytotoxic chemotherapy was introduced in combination with surgery and/or radiation (Fig. 1) (Millard & De Braganca, 2016; Tait, Thornton-Jones, Bloom, Lemerle, & Morris-Jones, 1990). Currently, cytotoxic chemotherapy combined with radiation continues to be used as the standard therapy for MB. However, the long-term use of these therapeutic regimes has shown to induce substantial toxic damages, most notably in developing young patients. The inability of the therapy to recognize both the inter- and intra-tumoral heterogeneity of MB subgroups and the lack of clinical biomarkers to stratify patients, are the major drawbacks underlying the adverse effects (Jakacki et al., 2012; Lannering et al., 2012).
Section snippets
Early classification of MB: From morphological to histological
When MB was first described in the 1930s, it was classified as a large subgroup of malignant invasive embryonal tumors of the cerebellum based on similar morphology with densely packed cells. Metastases of MB barely occur outside the central nervous system, but have been occasionally observed in the bone marrow, lymph nodes, and viscera (Eberhart, Cohen, Tihan, Goldthwaite, & Burger, 2003). In the 1980s the World Health Organization (WHO) classified MB into four main histologic types, namely,
Treatment challenges and current available therapies
Since MB tumors are located in the posterior fossa, early diagnosis and treatment are difficult and metastases often occur at diagnosis, which are the leading cause of mortality, especially for those high-risk MB patients. Maximal surgical resection followed by radiation and chemotherapy is the current standard therapy. However, >25% of patients experience cerebella mutism, dysarthria and neurocognitive disorders after surgical operation, and the adjuvant craniospinal radiotherapy and
Concluding remarks and future perspectives
MB is the most common and yet highly heterogeneous childhood malignant brain tumor. Since MB occurs in the posterior fossa, discrimination is difficult and 70–80% of MB patients are diagnosed before metastatic dissemination survive, thus making treatment of this disease even harder (Quinlan & Rizzolo, 2017). Recent application of new genomic and epigenetic profiling technologies has revolutionized the classification of MB from strictly morphology-based to molecular and epigenetic
Declaration of Competing Interest
The authors declare that there are no conflicts of interest.
Acknowledgements
This work was supported by grants from National Natural Science Foundation of China (Grants 81773565). Supporting grants from the Key Program of the Frontier Science (Grant 160621) of the Chinese Academy of Sciences, and the Strategic Leading Project A on Precision Medicine of the Chinese Academy of Sciences (XDA12020374, XDA12020226, XDA1250400) are also highly appreciated. A start-up grant to the Research Laboratory of Medicinal Chemical Biology & Frontiers on Drug Discovery (RLMCBFDD) from
References (106)
- et al.
Smoothened variants explain the majority of drug resistance in basal cell carcinoma
Cancer Cell
(2015) - et al.
Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics
Neuroscience
(2014) - et al.
From one to many: Further refinement of medulloblastoma subtypes offers promise for personalized therapy
Cancer Cell
(2017) - et al.
A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival
Chemical Biology
(2012) - et al.
Targeting GLI factors to inhibit the hedgehog pathway
Trends in Pharmacological Sciences
(2015) - et al.
Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against vismodegib-resistant smoothened mutant
European Journal of Pharmacology
(2014) - et al.
Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
Cancer Cell
(2013) - et al.
Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth
Cancer Cell
(2010) - et al.
Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: A systemic review and meta-analysis
Acta Neuropathologica Communications
(2019) - et al.
The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers
Journal of Biological Chemistry
(2014)
Discovery of the investigational drug TAK-441, a pyrrolo[3,2-c]pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: Modification of the core skeleton for improved solubility
Bioorganic & Medicinal Chemistry
Hedgehog signal transduction: Key players, oncogenic drivers, and cancer therapy
Developmental Cell
GDC-0449-a potent inhibitor of the hedgehog pathway
Bioorganic & Medicinal Chemistry Letters
Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/−) p53(−/−) mice
Cancer Cell
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: A cohort study
Lancet Oncology
Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding
Oncotarget
Target identification for a hedgehog pathway inhibitor reveals the receptor GPR39
Nature Chemistry Biology
The landscape of somatic copy-number alteration across human cancers
Nature
Targeting Gli transcription activation by small molecule suppresses tumor growth
Oncogene
Cooperation between the Hic1 and Ptch1 tumor suppressors in medulloblastoma
Genes & Development
Structural basis of smoothened regulation by its extracellular domains
Nature
Nature Cell Biology
FDA approval summary: Sonidegib for locally advanced basal cell carcinoma
Clinical Cancer Research
Intertumoral heterogeneity within medulloblastoma subgroups
Cancer Cell
Structural basis of SUFU-GLI interaction in human Hedgehog signaling regulation
Acta Crystallographica Section D Biological Crystallogrphy
Gli2 acetylation at lysine 757 regulates hedgehog-dependent transcriptional output by preventing its promoter occupancy
PLoS One
An investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patient resistant to vismodegib
Clinical Cancer Research
Histone deacetylase 6 represents a novel drug target in the oncogenic hedgehog signaling pathway
Molecular Cancer Therapeutics
Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance
Cancer Research
Vismodegib
Nature Reviews Drug Discovery
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma
Acta Neuropathologica
Medulloblastomas with systemic metastases: Evaluation of tumor histopathology and clinical behavior in 23 patients
Journal of Pediatric Hematology/Oncology
Histopathologic grading of medulloblastomas: A pediatric oncology group study
Cancer
Childhood medulloblastoma: Novel approaches to the classification of a heterogeneous disease
Acta Neuropathologica
Medulloblastoma: Clinicopathological correlates of, SHH, WNT, and non-SHH/WNT molecular subgroups
Acta Neuropathologica
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables
Journal of Clinical Oncology
Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas-implications for tumor biology and potential clinical utility
Oncogene
Small molecule Hedgehog inhibitor attenuates the leukemia initiation potential of acute myeloid leukemia cells
Cancer Science
Clinical Cancer Research
A hematogenous route for medulloblastoma leptomeningeal metastases
Cell
Altered neural cell fates and medulloblastoma in mouse patched mutants
Science
Discovery and preclinical development of Vismodegib
Expert Opinion on Drug Discovery
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with smoothened inhibitor resistance
Oncotarget
The Smo/Smo model: Hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread
Cancer Research
Medulloblastomics revisited: Biological and clinical insights from thousands of patients
Nature Review Cancer
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
Nature
Cellular cholesterol directly activates smoothened in hedgehog signaling
Cell
One hundred faces of cyclopamine
Current Pharmaceutical Design
Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: A children’s oncology group phase I/II study
Journal of Clinical Oncology
Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma
Acta Neuropathologica Communications
Cited by (40)
The Role of Chemotherapy in the Treatment of Adult Medulloblastoma
2022, World NeurosurgeryExosomal microRNAs induce tumor-associated macrophages via PPARγ during tumor progression in SHH medulloblastoma
2022, Cancer LettersCitation Excerpt :The SHH subgroup represents about 30% of all MB cases and is characterized by aberrant activation of the sonic hedgehog (SHH) pathway [3], which regulates cerebellar granule neuron progenitors (CGNPs) proliferation during embryonic development and also promotes tumorigenesis [4]. Anti-SHH drugs targeting Smoothened (SMO), a G-protein-coupled receptor transporting the SHH signal across the cell membrane, have been applied in clinical trial [5]. However, emerging drug resistance in MB patients has been reported to limit the antineoplastic efficacy of SMO inhibitors as monotherapy [6].
Steroidal alkaloids isolated from Veratrum grandiflorum Loes. as novel Smoothened inhibitors with anti-proliferation effects on DAOY medulloblastoma cells
2021, Bioorganic and Medicinal ChemistryCitation Excerpt :This may have occurred because their abilities to binding with Smo were not stronger than that of cyclopamine.32 Medulloblastoma (MB) is a common pediatric brain tumor and approximately 30% of MB patients are placed in the SHH subgroup of MB, which is characterized by activation of the Hh signaling pathway.35 The MB cell line DAOY presents a high response to the Hh signaling pathway,2 therefore we use it to evaluate the anti-proliferation effects of these natural Smo inhibitors by MTT bioassay.
Medulloblastoma drugs in development: Current leads, trials and drawbacks
2021, European Journal of Medicinal ChemistryCitation Excerpt :Adult Hh-MBs are characterized by a higher prevalence of Hh pathway-associated mutations to infants. Many small molecule inhibitors targeting the somatic mutations or gene amplifications of the Hh-signaling pathway have been evaluated extensively in preclinical and clinical trials and several compounds have been approved for clinical use [5]. Wnt-MB patients are primarily composed of older children with a median age of diagnosis around 11 years.
Aging-Related Functional and Structural Changes in Renal Tissues: Lesson from a Camel Model
2021, Microscopy and MicroanalysisSALL4 is a CRL3<sup>REN/KCTD11</sup> substrate that drives Sonic Hedgehog-dependent medulloblastoma
2024, Cell Death and Differentiation